Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,367Revenue $M274Net Margin (%)34.2Z-Score35.4
Enterprise Value $M2,184EPS $1.6Operating Margin %52.7F-Score7
P/E(ttm))19.5Cash Flow Per Share $0.4Pre-tax Margin (%)53.1Higher ROA y-yY
Price/Book6.210-y EBITDA Growth Rate %0Quick Ratio6.8Cash flow > EarningsN
Price/Sales6.55-y EBITDA Growth Rate %29.2Current Ratio7.7Lower Leverage y-yY
Price/Cash Flow14.2y-y EBITDA Growth Rate %468ROA % (ttm)36.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)41.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M35.8ROI % (ttm)8.9Gross Margin Increase y-yY

Gurus Latest Trades with LCI

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LCIJoel Greenblatt 2014-12-31 Add0.25%$40.3 - $57.52
($46.48)
$ 66.1230%Add 238.24%1,026,029
LCIJoel Greenblatt 2014-09-30 Add0.12%$34.05 - $51.19
($39.77)
$ 66.1240%Add 749.49%303,345
LCIJoel Greenblatt 2014-06-30 Buy 0.02%$29.62 - $49.76
($39.16)
$ 66.1241%New holding35,709
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LCI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


LCI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schreck WilliamCOO 2015-03-16Sell134,635$64.990.8view
BEDROSIAN ARTHUR PCEO 2015-03-16Sell5,000$65.230.43view
Schreck WilliamCOO 2015-03-12Sell16,177$65.10.63view
Taveira PaulDirector 2015-03-06Sell2,500$63.073.87view
Schreck WilliamCOO 2015-03-06Sell50,000$63.353.41view
Drabik David ADirector 2015-02-18Sell12,500$61.556.43view
BEDROSIAN ARTHUR PCEO 2015-02-17Sell5,000$59.899.38view
Landis G. MichaelPrincipal Accounting Officer 2015-02-17Sell11,500$58.611.79view
FARBER JEFFREYDirector 2015-02-13Sell35,000$58.1812.6view
SMITH KEVINVice President 2015-02-11Sell109,436$56.5115.93view

Press Releases about LCI :

    Quarterly/Annual Reports about LCI:

    News about LCI:

    Articles On GuruFocus.com
    Pharmaceutical Stock Picks For March Mar 04 2015 
    My Stocks Feb 13 2015 
    My Stocks Feb 13 2015 
    Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
    comment on LCI Nov 19 2012 
    comment on LCI Nov 13 2012 
    comment on LCI Jan 26 2012 
    comment on LCI Jan 26 2012 
    comment on LCI Jan 23 2012 
    comment on LCI Jan 23 2012 

    More From Our Partners
    Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog Mar 27 2015 - ZACKS

    More From Other Websites
    Hot Growth Stocks: How Is Lannett's Latest Breakout? Mar 27 2015
    Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog Mar 27 2015
    Which 4 Big Drugmakers Have Rising Estimates? Mar 27 2015
    Calithera Biosciences (CALA) Crumbles: Stock Falls by 7.3% - Tale of the Tape Mar 27 2015
    Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog Mar 26 2015
    Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog Mar 26 2015
    Oncolytics' Cancer Drug Reolysin Gets Orphan Status in EU - Analyst Blog Mar 26 2015
    Indexes Stall Near Flat Line; Lannett Up Some More Mar 26 2015
    ZS Pharma (ZSPH) Crumbles: Stock Falls by 9.9% - Tale of the Tape Mar 26 2015
    Weakness Seen in Sage Therapeutics (SAGE): Stock Falls 13.2% - Tale of the Tape Mar 26 2015
    BioLineRx (BLRX) Looks Good: Stock Moves 9.1% Higher - Tale of the Tape Mar 25 2015
    Zafgen (ZFGN) Crumbles: Stock Falls by 7.9% - Tale of the Tape Mar 25 2015
    Pfizer & Eli Lilly to Resume Phase III Study of Tanezumab - Analyst Blog Mar 24 2015
    Calithera Biosciences (CALA) Jumps: Stock Rises 19% - Tale of the Tape Mar 24 2015
    Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog Mar 23 2015
    Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog Mar 23 2015
    Concert Pharmaceuticals (CNCE) in Focus: Stock Tumbles 10.8% - Tale of the Tape Mar 20 2015
    Tetraphase Closes Public Offering, to Raise $173.1M - Analyst Blog Mar 19 2015
    Vertex's Kalydeco Gets FDA Nod for Additional Indication - Analyst Blog Mar 19 2015
    Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog Mar 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK